pre-IPO PHARMA

COMPANY OVERVIEW

Lycera is a private biopharmaceutical company that is developing novel small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer. Based on its world-class R&D engine, Lycera is advancing clinical candidates from distinct, yet complementary , areas of research, including immune metabolism, cell signaling, and immune cell differentiation.


LOCATION

  • New York, NY, USA
  • Ann Arbor, MI, USA
  • Plymouth Meeting, PA, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Oncology

  • WEBSITE

    https://lycera.com


    CAREER WEBSITE

    http://www.lycera.com/careers


    SOCIAL MEDIA


    INVESTORS

    arch-venture-partners clarus-ventures edf-ventures interwest-partners


    PRESS RELEASES


    Oct 10, 2018

    Lycera Announces Presentations at the 2018 ESMO Congress for LYC-55716, a First-in-class RORgamma Agonist Candidate


    May 30, 2018

    Lycera to Present on First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 ASCO Annual Meeting


    May 16, 2018

    Lycera Announces Publication of Preclinical Immuno-Oncology Research, Demonstrating that Treatment with RORgamma Agonists Enhances CAR T-Cell Anti-Tumor Activity and Persistence, Resulting in Long-Lasting Anti-Tumor Memory T-Cells in an In Vivo Model


    Apr 17, 2018

    Lycera Presents Clinical Safety and Dose Selection Results for First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 AACR Annual Meeting


    Apr 5, 2018

    Lycera to Present Clinical Results and Supporting Preclinical Data for First-In-Class RORgamma Agonist LYC-55716 at the 2018 AACR Annual Meeting


    For More Press Releases


    Google Analytics Alternative